Lupin, Mark Cuban Cost Plus Drug Company and COPD Foundation collaborate to expand access to medication for COPD patients

Mumbai: Global pharma major Lupin Limited has forged a unique collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) and the COPD Foundation.

This collaboration aims to bolster access to healthcare by expanding the availability of TiotropiumBromide Inhalation Powder, 18 mcg/capsule, to COPD patients in the US. Lupin’s Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, is a generic product that is therapeutically equivalent to Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule by Boehringer Ingelheim Pharmaceuticals, Inc.

Chronic obstructive pulmonary disease (COPD) affects over 15 million adults in the US and ranks as the fourth leading cause of death in the country.

Spiro Gavaris, President US Generics, Lupin said, “We believe there is a large unmet need for improved and affordable products for patients in the US. As a leading healthcare organization, we are committed to increasing access for patients, seeking treatment options for respiratory conditions like COPD, with our respiratory portfolio and pipeline. Our collaboration with Mark Cuban Cost Plus Drug Company and the COPD Foundation reflects our intent to provide quality treatment options for patients.”